UBS Says GLP-1 Weight-Loss Drugs Reduce Restaurant Sales
UBS stated that rising use of GLP-1 weight-loss drugs could lower restaurant sales as users reduce calorie intake and eat out less. The bank expects restaurants to adjust menus with smaller portions and healthier items.
foxnews.comUBS reported that increasing use of GLP-1 weight-loss drugs may reduce restaurant sales. The bank said users are cutting calories, dining out less frequently, and choosing healthier foods. The bank expects restaurants to respond by offering smaller portions and adding healthier menu options.
Fast-food and less-healthy chains face the highest exposure, according to UBS. UBS did not provide specific sales forecasts or name individual restaurant companies in the statement.
Key Facts
Potential Impact
- 01
Restaurants may introduce smaller portions and healthier menu items.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.